Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting April 20, 2026 depression ONLY AVAILABLE IN PAID PLANS. Originally reported by benzinga. Read more Source: https://www.benzinga.com/pressreleases/26/04/g51904056/xenon-presents-azetukalner-phase-3-x-tole2-study-results-and-48-month-long-term-data-in-focal-onse
